A single oral dose of geranylgeranylacetone attenuates kainic acid-induced seizures and neuronal cell death in rat hippocampus.
The present study evaluated the potential effect of geranylgeranylacetone (GGA), which is known as an antiulcer agent, against kainic acid (KA)-induced neurotoxicity. Pretreatment with a single oral GGA dose (800 mg/kg, 2 days before KA) significantly attenuated KA-induced seizures and cell death in rat hippocampus. These effects of GGA were prevented by the coinjection of MK801, a noncompetitive N-methyl-D-aspartate glutamate receptor antagonist, which indicates that the protection was indeed mediated by glutamate receptor activation.
Fujiki
Minoru
M
Department of Neurosurgery, School of Medicine, Oita University, 1-1, Idaigaoka, Hasama-machi, 879-5593 Oita, Japan. fujiki@med.oita-u.ac.jp
Kobayashi
Hidenori
H
Inoue
Ryo
R
Ishii
Keisuke
K
D000284:Administration, Oral; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D016923:Cell Death / Q000187:drug effects*; D003292:Convulsants / Q000494:pharmacology; D004224:Diterpenes / Q000008:administration & dosage*; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology; D007608:Kainic Acid / Q000494:pharmacology; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000473:pathology; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017470:Receptors, Glutamate / Q000187:drug effects / Q000502:physiology; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy*
D000897:Anti-Ulcer Agents; D003292:Convulsants; D004224:Diterpenes; D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D017470:Receptors, Glutamate; D016291:Dizocilpine Maleate; C031049:geranylgeranylacetone; D007608:Kainic Acid